Skip to main content
NCBI home page
Canadian Medical Association Journal logoLink to Canadian Medical Association Journal
. 1965 Jul 31;93(5):189–197.

Myasthenia Gravis: Medical Aspects

Ludmila R Zeldowicz, William St John Buckler
PMCID: PMC1928601  PMID: 14323662

Abstract

The diagnosis of myasthenia gravis is often difficult and calls for a broader use of pharmacological and electrodiagnostic tests. The decamethonium-edrophonium test, which has proved superior to other procedures for this purpose, is based on neurophysiological principles and depicts the behaviour of the neuromuscular junction. A state of resistance to depolarizing agents in the limited form of myasthenia and a state of a non-depolarizing (competitive) block in advanced cases has been shown. This test has demonstrated that the neuromuscular defect exists throughout the skeletal musculature, including muscles clinically unaffected. It produced no false-positive results either in normal or neurasthenic persons or in patients with neurological diseases with myasthenic symptoms. In a patient with botulism and in a patient with ocular palsies from brain-stem encephalitis the edrophonium test gave a false-positive result, while the decamethonium-edrophonium test was negative.

Diagnosis, treatment and management of myasthenic emergencies are described.

Full text

PDF
189

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. CHURCHILL-DAVIDSON H. C., RICHARDSON A. T. The action of decamethonium iodide (C.10) in myasthenia gravis. J Neurol Neurosurg Psychiatry. 1952 May;15(2):129–133. doi: 10.1136/jnnp.15.2.129. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. FRASER D., TURNER J. W. Myasthenia gravis and pregnancy. Lancet. 1953 Aug 29;265(6783):417–419. doi: 10.1016/s0140-6736(53)90201-3. [DOI] [PubMed] [Google Scholar]
  3. FRENKEL M. TREATMENT OF MYASTHENIA GRAVIS BY OVULATORY SUPPRESSION. Arch Neurol. 1964 Dec;11:613–617. doi: 10.1001/archneur.1964.00460240045006. [DOI] [PubMed] [Google Scholar]
  4. GOTTLIEB B., LAURENT L. P. Spironolactone in the treatment of myasthenia gravis. Lancet. 1961 Sep 2;2(7201):528–529. doi: 10.1016/s0140-6736(61)92962-2. [DOI] [PubMed] [Google Scholar]
  5. GROB D., JOHNS R. J., HARVEY A. M. Alterations in neuromuscular transmission in myasthenia gravis as determined by studies of drug action. Am J Med. 1955 Nov;19(5):684–690. doi: 10.1016/s0002-9343(55)80008-3. [DOI] [PubMed] [Google Scholar]
  6. JENKINS L. C., CHANG J., SAXTON G. D. MYASTHENIA GRAVIS: ANESTHETIC AND SURGICAL MANAGEMENT OF THE PATIENT UNDERGOING THYMECTOMY. Can Med Assoc J. 1965 Jul 31;93:198–203. [PMC free article] [PubMed] [Google Scholar]
  7. KEYNES G. Obstetrics and gynaecology in relation to thyrotoxicosis and myasthenia gravis. J Obstet Gynaecol Br Emp. 1952 Apr;59(2):173–182. doi: 10.1111/j.1471-0528.1952.tb04112.x. [DOI] [PubMed] [Google Scholar]
  8. LEOPOLD I. H., HEDGES T. R., Jr, MONTANA J., KRISHNA N., BECKETT S. Local administration of anticholinesterase agents in ocular myasthenia gravis. Arch Ophthalmol. 1960 Mar;63:544–547. doi: 10.1001/archopht.1960.00950020546012. [DOI] [PubMed] [Google Scholar]
  9. MCQUILLEN M. P., GROSS M., JOHNS R. J. Chlorpromazine-induced weakness in myasthenia gravis. Arch Neurol. 1963 Mar;8:286–290. doi: 10.1001/archneur.1963.00460030070006. [DOI] [PubMed] [Google Scholar]
  10. NASTUK W. L., PLESCIA O. J., OSSERMAN K. E. Changes in serum complement activity in patients with myasthenia gravis. Proc Soc Exp Biol Med. 1960 Oct;105:177–184. doi: 10.3181/00379727-105-26050. [DOI] [PubMed] [Google Scholar]
  11. NORRIS F. H., Jr, COLELLA J., MCFARLIN D. EFFECT OF DIPHENYLHYDANTOIN ON NEUROMUSCULAR SYNAPSE. Neurology. 1964 Sep;14:869–876. doi: 10.1212/wnl.14.9.869. [DOI] [PubMed] [Google Scholar]
  12. OSSERMAN K. E., TENG P. Studies in myasthenia gravis: neonatal and juvenile types. J Mt Sinai Hosp N Y. 1956 Sep-Oct;23(5):711–727. [PubMed] [Google Scholar]
  13. SOMERS J. E., IRWIN R. L., SHY G. M. The use of lycoramine derivatives in myasthenia gravis. Neurology. 1963 Jul;13:543–553. doi: 10.1212/wnl.13.7.543. [DOI] [PubMed] [Google Scholar]
  14. VAN DER GELD H., FELTKAMP T. E., VAN LOGHEM J., OOSTERHUIS H. J., BIEMOND A. MULTIPLE ANTIBODY PRODUCTION IN MYASTHENIA GRAVIS. Lancet. 1963 Aug 24;2(7304):373–375. doi: 10.1016/s0140-6736(63)93055-1. [DOI] [PubMed] [Google Scholar]
  15. ZELDOWICZ L. Paroxysmal motor episodes as early manifestations of multiple sclerosis. Can Med Assoc J. 1961 Apr 29;84:937–941. [PMC free article] [PubMed] [Google Scholar]

Articles from Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES